DIAVACS
The company potentially addresses the disadvantages of prior approaches by offering local antigen-specific immunosuppression, halting the pathogenic autoimmune response without compromising the body's immune system, and complements emerging regenerative approaches by protecting newly created beta cells from autoimmune attack, enabling patients to get rid from lifelong dependency on insulin.
DIAVACS
Industry:
Biotechnology Health Diagnostics Therapeutics
Founded:
2013-01-01
Address:
Edgewater, New Jersey, United States
Country:
United States
Total Employee:
51+
Status:
Active
Total Funding:
850 K USD
Technology used in webpage:
OpenResty
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Advisors List
Current Employees Featured
Founder
More informations about "DiaVacs"
DiaVacs Immunotherapy – Cell-Based Type 1 Diabetes and SARS …
Dendritic cells and the control of immunity. Morgan; June 18, 2021 April 28, 2021; 0 ; Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.See details»
DiaVacs - Crunchbase Company Profile & Funding
DiaVacs Immunotherapy: A cell-based therapy aimed at treating Type 1 Diabetes and SARS-CoV-2. SARS-CoV-2 Rapid Antigen Test: A rapid test for qualitative detection of SARS-CoV-2 …See details»
ABOUT US – DiaVacs Immunotherapy
DiaVacs, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Jun 18, 2023 Explore DiaVacs, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 1 news, Disease Domain:Immune System Diseases, Endocrinology ...See details»
DiaVacs Company Profile 2024: Valuation, Funding & Investors
DiaVacs General Information Description. Developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependence. The company potentially …See details»
DiaVacs - Funding, Financials, Valuation & Investors - Crunchbase
DiaVacs is a developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependence ... Products. Resources. Pricing. Resources. Log In. Organization. …See details»
TECHNOLOGY – DiaVacs Immunotherapy
May 4, 2021 Diavacs’ technology engineers the DCs that drive the autoimmune attack into “regulatory dendritic cells” (DC regs) that suppress the autoimmune attack. Diavacs’ …See details»
Organization | DiaVacs, Inc.
DiaVacs, Inc. Report issue. For profit Phase 2. Founded: Edgewater NJ United States (2013 ... Organization Overview. First Clinical Trial. 2015 NCT02354911. First Marketed Drug. None …See details»
DiaVacs - Contacts, Employees, Board Members, Advisors & Alumni
DiaVacs is a developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependence ... Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
Dendritic Cells(DiaVacs) - Drug Targets, Indications, Patents
Dendritic Cells(DiaVacs): a Cell replacements Drug, Initially developed by DiaVacs, Inc., Mechanism: Cell replacements. Biomedical products. Data. Feature. Plans. Sign Up for Free. …See details»
DiaVacs - Products, Competitors, Financials, Employees, …
(Synthorx photo) DiaVacs DiaVacs aims to treat type 1 diabetes by re-engineering dendritic cells, the orchestra leaders of the immune system, to protect insulin-producing pancreatic cells …See details»
DiaVacs | Biotechnology | The Pharmaletter | The Pharmaletter
DiaVacs is a clinical stage biotechnology company focused on curing auto-immune diseases.See details»
DiaVacs Announces a Strategic Collaboration with Profil Institute …
Feb 12, 2014 /PRNewswire/ -- DiaVacs, Inc., ... Profil Institute for Clinical Research, Inc. is an early phase clinical research organization focused on diabetes and obesity. The company is …See details»
Divacs - Company Profile - Tracxn
Divacs - Autologous dendritic cell therapy to reverse the onset of autoimmune diseases such as Type 1 diabetes.. Raised a total funding of $850K over 1 round. Divacs has 416 competitors.See details»
DiaVacs - Crunchbase
DiaVacs is a developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependenceSee details»
Autologous dendritic cell immunotherapy - DiaVacs - AdisInsight
DiaVacs was developing an autologous dendritic cell immunotherapy, designated DV 0100, for the intradermal treatment of type 1 diabetes mellitus. Dendritic Autologous dendritic cell …See details»
DiaVacs - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. DiaVacs . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 9. About. DiaVacs is …See details»
A new generation of Ca2+ indicators with greatly improved
Jun 25, 2021 A new family of highly fluorescent indicators has been synthesized for biochemical studies of the physiological role of cytosolic free Ca2+. The compounds combine an 8 …See details»
DiaVacs: Uses, Interactions, Mechanism of Action - DrugBank Online
Sep 27, 2023 DiaVacs DrugBank Accession Number DB18512 Background. DiaVacs is a CD40/CD80/CD86 modified autologous dendritic cell therapy. Type Biotech Groups …See details»
DiaVacs - Updates, News, Events, Signals & Triggers - Crunchbase
DiaVacs is a developer of biotechnological products and drugs designed to liberate patients from lifelong insulin dependenceSee details»